NRAS and melanoma: Based on a number of Next Generation Sequencing studies involving hundreds of melanomas, a molecular disease model of melanoma has been proposed, whereby ~40-50% of melanomas from patients carry mutations in the BRAF gene, with ~90% of these BRAF mutations being a BRAFV600E mutation, and a further 20% carry mutations in the NRAS gene [6].